FDA Launches Major Initiatives for Drug Manufacturing and Food Safety

The U.S. Food and Drug Administration (FDA) has announced a comprehensive suite of initiatives aimed at transforming the country’s pharmaceutical and food systems. These initiatives focus on onshoring drug manufacturing, revising food labeling regulations, and enhancing enforcement against non-approved weight-loss drugs.

On February 1, 2026, the FDA commenced its FDA PreCheck pilot program, a strategic move to strengthen the domestic pharmaceutical supply chain. This program enables manufacturers to engage with FDA representatives earlier in the regulatory process, fostering an environment conducive to building drug manufacturing facilities within the United States. The FDA aims to expedite the transition from construction to production, ultimately enhancing the availability of critical medications in the U.S. market.

The PreCheck program is structured in two phases. Initially, FDA staff will collaborate with manufacturers during the development of their facilities, providing technical guidance and conducting pre-operational reviews before the plants become fully operational. The second phase will involve coordinated efforts through pre-submission meetings and inspections, which will streamline the review process for specific drug applications.

The FDA has stated that the pilot program was developed following extensive industry feedback collected during a public meeting on drug manufacturing held in September 2025, as well as through comments submitted via the Federal Register.

In a related effort, on February 5, 2026, the FDA introduced new guidelines to facilitate the removal of artificial petroleum-based colors from food products. Companies will now be permitted to label their products as containing “no artificial colors” if they avoid petroleum-based dyes, even when using colors derived from natural sources. Previously, such claims were restricted to products devoid of any added color.

This regulatory change represents a significant shift in food labeling policy. The FDA announced it would exercise enforcement discretion for these voluntary labeling claims and has communicated this adjustment to industry stakeholders. Additionally, the agency has approved new color additives, including beetroot red and an expanded use of spirulina extract, bringing the total number of approved natural color options to six under the current administration.

The FDA, in collaboration with the Department of Health and Human Services, has been monitoring industry commitments to eliminate petroleum-based dyes from food products. Progress is being documented online to ensure transparency in these efforts.

On February 6, 2026, the FDA took a firmer stance by announcing plans to restrict the use of GLP-1 active pharmaceutical ingredients in non-FDA-approved compounded drugs. These products, which are marketed as alternatives to approved treatments, have raised safety and efficacy concerns. The FDA emphasized that it cannot verify the safety or effectiveness of these compounded products and warned that companies making unsubstantiated claims may face legal repercussions.

The agency is also enhancing its scrutiny of direct-to-consumer advertising, following a series of warning letters sent out in late 2025. Companies have been reminded that they cannot equate compounded products with FDA-approved drugs or assert that these products deliver clinically proven results.

These initiatives signify a more assertive regulatory approach by the FDA. By combining incentives to bolster domestic drug manufacturing, modifying food labeling regulations, and increasing enforcement against potentially misleading pharmaceutical practices, the agency is taking significant steps to improve public health and safety in the United States.